Baxter International (NYSE:BAX) had its price target raised by Citigroup from $66.00 to $70.00 in a research report report published on Tuesday, MarketBeat reports. Citigroup currently has a neutral rating on the medical instruments supplier’s stock.
A number of other equities analysts have also recently commented on the company. Royal Bank of Canada reaffirmed a hold rating and issued a $72.00 target price on shares of Baxter International in a report on Friday, February 2nd. Barclays raised their target price on Baxter International from $73.00 to $77.00 and gave the stock an overweight rating in a report on Friday, February 2nd. BMO Capital Markets raised their target price on Baxter International from $74.00 to $77.00 and gave the stock an outperform rating in a report on Friday, February 2nd. Zacks Investment Research raised Baxter International from a sell rating to a hold rating in a report on Thursday, January 4th. Finally, Raymond James Financial raised Baxter International from a market perform rating to an outperform rating and set a $73.00 price target on the stock in a report on Wednesday, January 3rd. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $70.36.
Baxter International (NYSE BAX) opened at $66.67 on Tuesday. Baxter International has a twelve month low of $48.15 and a twelve month high of $72.58. The company has a market capitalization of $35,697.38, a price-to-earnings ratio of 51.68, a P/E/G ratio of 1.85 and a beta of 0.78. The company has a quick ratio of 2.22, a current ratio of 2.80 and a debt-to-equity ratio of 0.37.
In other Baxter International news, SVP Jeanne K. Mason sold 33,350 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $65.25, for a total value of $2,176,087.50. Following the completion of the sale, the senior vice president now owns 124,609 shares of the company’s stock, valued at $8,130,737.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Giuseppe Accogli sold 28,641 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The disclosure for this sale can be found here. 0.05% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in BAX. Acadian Asset Management LLC lifted its stake in Baxter International by 156.7% in the fourth quarter. Acadian Asset Management LLC now owns 657,855 shares of the medical instruments supplier’s stock worth $42,523,000 after purchasing an additional 401,532 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in Baxter International by 35.8% in the third quarter. Canada Pension Plan Investment Board now owns 1,413,054 shares of the medical instruments supplier’s stock worth $88,669,000 after purchasing an additional 372,500 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in Baxter International by 59.7% in the fourth quarter. Teacher Retirement System of Texas now owns 750,850 shares of the medical instruments supplier’s stock worth $48,535,000 after purchasing an additional 280,597 shares during the last quarter. Segall Bryant & Hamill LLC lifted its stake in Baxter International by 209.0% in the third quarter. Segall Bryant & Hamill LLC now owns 412,054 shares of the medical instruments supplier’s stock worth $25,856,000 after purchasing an additional 278,685 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in Baxter International by 619.2% in the third quarter. Nordea Investment Management AB now owns 188,842 shares of the medical instruments supplier’s stock worth $11,850,000 after purchasing an additional 162,584 shares during the last quarter. 83.54% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This report was posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2018/02/07/baxter-international-bax-pt-raised-to-70-00.html.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.